Skip to content
Advertisement

, Johnson &Johnson

Latest Stories

med--johnson_and_johnson_settlement_06615.jpg

med--johnson_and_johnson_settlement_06615.jpg

Researchers are working to find alternatives to opioids to treat chronic pain. (Associated Press/File)

johnson_johnson-actelion_30426.jpg

johnson_johnson-actelion_30426.jpg

FILE - This Friday, Oct. 10, 2008, file photo illustration shows Johnson & Johnson products, in Philadelphia. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (AP Photo/Matt Rourke, File)

johnson_johnson-actelion_52638.jpg

johnson_johnson-actelion_52638.jpg

FILE - In this July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (AP Photo/Mel Evans, File)

johnson_johnson-actelion_37235.jpg

johnson_johnson-actelion_37235.jpg

FILE - This Thursday, Feb. 22, 2007, file photo shows the headquarters of biopharmaceutical company Actelion, in Allschwil, Switzerland. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (Georgios Kefalas/Keystone via AP, File)

earns_johnson_johnson_75733.jpg

earns_johnson_johnson_75733.jpg

FILE - In this July 16, 2012, file photo, Johnson & Johnson products are displayed in Orlando, Fla. On Tuesday, Jan. 24, 2017, Johnson & Johnson reports financial results. (AP Photo/John Raoux, File)